Silencing genes in the kidney: Antisense or RNA interference?

Nephrology Dialysis Transplantation

Volumn 23, Issue 7, 2008, Pages 2115-2118

  Wang, Jia Hui ^a   Hendry, Bruce M ^a   Sharpe, Claire C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antisense; Gene therapy; siRNA

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FOMIVIRSEN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

ANTISENSE THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GENE SILENCING; GENE TARGETING; HUMAN; KIDNEY; NONHUMAN; NOTE; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT INDICATION;

ANIMALS; GENE SILENCING; GENE THERAPY; HUMANS; KIDNEY; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 46849095341     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn095     Document Type: Note

References (34)

1. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008; 97: 225-236
2. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285-288
3. Loke SL, Stein CA, Zhang XH et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989; 86: 3474-3478
4. Zhang C, Meng X, Zhu Z et al. Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro. Cell Biol Int 2004; 28: 863-873
5. Sharpe CC, Dockrell ME, Noor MI et al. Role of Ras isoforms in the stimulated proliferation of human renal fibroblasts in primary culture. J Am Soc Nephrol 2000; 11: 1600-1606
6. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 107-129
7. Tereshko V, Portmann S, Tay EC et al. Correlating structure and stability of DNA duplexes with incorporated 2′-O-modified RNA analogues. Biochemistry 1998; 37: 10626-10634
8. Sands H, Gorey-Feret LJ, Cocuzza AJ et al. Biodistribution and metabolism of internally 3H-labeled oligonucleotides: I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 1994; 45: 932-943
9. Rappaport J, Hanss B, Kopp JB et al. Transport of phosphorothioate oligonucleotides in kidney: implications formolecular therapy. Kidney Int 1995; 47: 1462-1469
10. Cheng QL, Chen XM, Li F et al. Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction. Kidney Int 2000; 57: 183-190
11. Chen W, Langer RM, Janczewska S et al. Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicity. Transplantation 2005; 79: 401-408
12. Guha M, Xu ZG, Tung D et al. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. Faseb J 2007; 21: 3355-3368
13. Yokoi H, Mukoyama M, Nagae T et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-1440
14. Yamada M, Katsuma S, Adachi T et al. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc Natl Acad Sci USA 2005; 102: 7736-7741
15. Isaka Y, Akagi Y, Kaneda Y et al. The HVJ liposome method. Exp Nephrol 1998; 6: 144-147
16. Isaka Y, Tsujie M, Ando Y et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000; 58: 1885-1892
17. Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol Pathol 2003; 31(Suppl): 119-122
18. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84
19. Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004; 201: 66-83
20. Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase gene into Petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2: 279-289
21. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811
22. Zamore PD. Ancient pathways programmed by small RNAs. Science 2002; 296: 1265-1269
23. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498
24. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75-86
25. Birmingham A, Anderson EM, Reynolds A et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199-204
26. Layzer JM, McCaffrey AP, Tanner AK et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004; 10: 766-771
27. Ma Z, Li J, He F et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005; 330: 755-759
28. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-270
29. Bitko V, Musiyenko A, Shulyayeva O et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55
30. Reich SJ, Fosnot J, Kuroki A et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216
31. Hamar P, Song E, Kokeny G et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 14883-14888
32. Hwang M, Kim HJ, Noh HJ et al. TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006; 81: 48-54
33. Takabatake Y, Isaka Y, Mizui M et al. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 2005; 12: 965-973
34. Judge AD, Bola G, Lee AC et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13: 494-505